A number of targeted anticancer compounds are now in clinical testing through our own product programs and those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of each compound.

12 compounds in clinical testing

Last updated on April 24, 2015
Program
Cancer
Types
Phases
Ovarian, endometrial
Preclinical
Phase I
DLBCL
Preclinical
Phase I
Phase II
DLBCL, other B-cell malignancies
Preclinical
Phase I
AML
Preclinical
HER2+ mBC 2nd-line
Preclinical
Phase I
Phase II
Pivotal/
Phase III
Marketed
HER2+ mBC 1st line
Preclinical
Phase I
Phase II
Pivotal/
Phase III
HER2+ BC others
Preclinical
Phase I
Phase II
Pivotal/
Phase III
HER2+ gastric
Preclinical
Phase I
Phase II
Pivotal/
Phase III
HER2+ NSCLC
Preclinical
Phase I
Phase II
Multiple myeloma
Preclinical
Phase I
Phase II
Solid tumors
Preclinical
Phase I
Solid tumors
Preclinical
Phase I
Multiple myeloma
Preclinical
Phase I
Phase II
Breast, bladder
Preclinical
Phase I
Mesothelioma, ovarian
Preclinical
Phase I
Glioblastoma
Preclinical
Phase I
Kidney
Preclinical
Phase I
cKIT+ cancer
Preclinical
Phase I
Undisclosed
Preclinical
Undisclosed
Preclinical

Earlier stage compounds in development by ImmunoGen and our partners.

 ImmunoGen  Roche  Sanofi  Biotest  Bayer  Amgen  Novartis  Lilly

Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

* Therapeutic antibody

mBC: metastatic breast cancer BC: breast cancer NSCLC: non-small cell lung cancer DLBCL: diffuse large B-cell lymphoma

Based on information on clinicaltrials.gov or other public disclosures.


Last updated: April 24, 2015

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue